Nula Unveils New Class of Medicines for Metabolic Disease
Nula Therapeutics Targets Metabolic Disease via Groundbreaking Nuclear Envelope Restoration In a significant leap for cellular medicine, Nula Therapeutics has emerged to challenge the current paradigm of metabolic healthcare. The biotech startup is developing an entirely new class of medicines designed to combat metabolic dysfunction by targeting a previously overlooked cellular frontier: the nuclear envelope. … Read more